文献速递认知障碍与痴呆

脑脊液GAP-43与淀粉样蛋白阳性个体认知下降速率及痴呆进展的关联

Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals.
PubMed 文献 · Neurology · 2022-10-03

该回顾性研究基于ADNI队列786名参与者,检测脑脊液GAP-43水平并与阿尔茨海默病病理生物标志物进行横断面和纵向关联分析。结果显示,在淀粉样蛋白阳性个体中,基线GAP-43高水平与更差的脑代谢下降、脑萎缩、MMSE评分下降及最高的痴呆转化风险相关(HR=8.56,95%CI 4.94-14.80,p=1.5×10⁻¹⁴)。

要点

  • 淀粉样蛋白阳性者脑脊液GAP-43水平高于淀粉样蛋白阴性者,且不依赖认知状态。
  • 淀粉样蛋白阳性者中,基线GAP-43高者脑代谢下降、脑萎缩及MMSE评分下降更差。
  • 淀粉样蛋白阳性者中,基线GAP-43高者转化为AD痴呆风险最高(HR=8.56)。

核心结论

  • 在淀粉样蛋白阳性个体中,基线脑脊液GAP-43高水平与更侵袭性的神经退行性过程、更快的认知下降速率及更高的痴呆转化风险相关。

研究设计与样本

  • 回顾性研究,纳入ADNI队列786名参与者,分为CU Aβ阴性(n=197)、CU Aβ阳性(n=55)、MCI Aβ阴性(n=228)、MCI Aβ阳性(n=193)和AD痴呆Aβ阳性(n=113)。
  • 采用in-house ELISA法检测脑脊液GAP-43,进行横断面和纵向组间比较。
  • 使用线性回归模型(校正年龄、性别和诊断)检验AD生物标志物与GAP-43的关联。
  • 使用线性混合效应模型评估基线GAP-43对脑低代谢、萎缩和认知下降的预测。
  • 使用Cox比例风险回归模型检验基线GAP-43水平和Aβ状态对AD痴呆进展风险的影响。

主要发现

  • 淀粉样蛋白阳性者脑脊液GAP-43水平较淀粉样蛋白阴性者升高,独立于认知状态。
  • 在淀粉样蛋白阳性者中,基线GAP-43高者较GAP-43低者脑代谢下降更差(p=0.01)、脑萎缩更差(p=8.8×10⁻²⁷)、MMSE评分更差(p=0.03)。
  • 淀粉样蛋白阳性者中,基线GAP-43高者转化为AD痴呆风险最高(HR=8.56,95%CI 4.94-14.80,p=1.5×10⁻¹⁴)。
  • 脑脊液tTau和pTau对GAP-43的效应量大于Aβ PET(η² pTau-181=0.53,P pTau-181<0.001;η² tTau=0.59,P tTau<0.001;η² Aβ PET=0.09,P Aβ PET<0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To test the associations between the presynaptic growth-associated protein 43 (GAP-43), quantified in CSF, and biomarkers of Alzheimer disease (AD) pathophysiology, cross-sectionally and longitudinally. METHODS: In this retrospective study, GAP-43 was measured in participants from the AD Neuroimaging Initiative (ADNI) cohort using an in-house ELISA method, and levels were compared between groups, both cross-sectionally and longitudinally. Linear regression models tested the associations between biomarkers of AD (amyloid beta [Aβ] and tau pathologies, neurodegeneration, and cognition) adjusted by age, sex, and diagnosis. Linear mixed-effect models evaluated how baseline GAP-43 predicts brain hypometabolism, atrophy, and cognitive decline over time. Cox proportional hazard regression models tested how GAP-43 levels and Aβ status, at baseline, increased the risk of progression to AD dementia over time. RESULTS: This study included 786 participants from the ADNI cohort, which were further classified in cognitively unimpaired (CU) Aβ-negative (nCU- = 197); CU Aβ-positive (nCU+ = 55), mild cognitively impaired (MCI) Aβ-negative (nMCI- = 228), MCI Aβ-positive (nMCI+ = 193), and AD dementia Aβ-positive (nAD = 113). CSF GAP-43 levels were increased in Aβ-positive compared with Aβ-negative participants, independent of the cognitive status. In Aβ-positive participants, high baseline GAP-43 levels led to worse brain metabolic decline (p = 0.01), worse brain atrophy (p = 8.8 × 10-27), and worse MMSE scores (p = 0.03) over time, as compared with those with low GAP-43 levels. Similarly, Aβ-positive participants with high baseline GAP-43 had the highest risk to convert to AD dementia (hazard ratio [HR = 8.56, 95% CI 4.94-14.80, p = 1.5 × 10-14]). Despite the significant association with Aβ pathology (η2 Aβ PET = 0.09, P Aβ PET < 0.001), CSF total tau (tTau) and phosphorylated tau (pTau) had a larger effect size on GAP43 than Aβ PET (η2 pTau-181 = 0.53, P pTau-181 < 0.001; η2 tTau = 0.59, P tTau < 0.001). DISCUSSION: High baseline levels of CSF GAP-43 are associated with progression in Aβ-positive individuals, with a more aggressive neurodegenerative process, faster rate of cognitive decline, and increased risk of converting to dementia.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Öhrfelt A, Benedet AL, Ashton NJ, et al. Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals. Neurology. 2022. PMID: 36192174. doi:10.1212/WNL.0000000000201417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。